Headlines about Eli Lilly and (NASDAQ:LLY
) have been trending somewhat positive recently, according to Accern. Accern identifies negative and positive press coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Eli Lilly and earned a coverage optimism score of 0.10 on Accern’s scale. Accern also gave media coverage about the company an impact score of 45.8948597234855 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.
Shares of Eli Lilly and (NASDAQ LLY
) traded down 1.26% during mid-day trading on Tuesday, reaching $85.95. The company had a trading volume of 2,142,748 shares. Eli Lilly and has a 52 week low of $64.18 and a 52 week high of $89.09. The company has a market capitalization of $90.68 billion and a price-to-earnings ratio of 37.19. The stock has a 50 day moving average of $82.49 and a 200-day moving average of $82.14.
COPYRIGHT VIOLATION WARNING: “Eli Lilly and (LLY ) Given News Sentiment Rating of 0.10” was posted by Community Financial News and is owned by of Community Financial News. If you are accessing this piece of content on another publication, it was copied illegally and republished in violation of US and international trademark and copyright laws. The legal version of this piece of content can be viewed at https://www.com-unik.info/2017/10/10/eli-lilly-and-lly-given-news-sentiment-rating-of-0-10.html.
Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.
What are top analysts saying about Eli Lilly and Co? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Eli Lilly and Co and related companies.